Evidence map›Paper›PMID 25444643›Full record

ArticlePsychoneuroendocrinology2015

Conditioned fear and extinction learning performance and its association with psychiatric symptoms in active duty Marines.

D T Acheson, M A Geyer, D G Baker, C M Nievergelt, K Yurgil, V B Risbrough, MRS-II Team

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Psychoneuroendocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03376139 (Zonisamide as a New Treatment for Post-Traumatic Stress Disorder and Co-Occurring Alcohol Use Disorder), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03376139 phase2withdrawnnot on this mapstarted 2019, after this paper: background citation

Zonisamide as a New Treatment for Post-Traumatic Stress Disorder and Co-Occurring Alcohol Use Disorder

TypeinterventionalSponsorPharmacotherapies for Alcohol and Substance Use Disorders AllianceRan2019 to 2019Enrolled0ConditionsPost Traumatic Stress Disorder, Alcohol Use DisorderArmsZonisamide, Placebo Comparator
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Understanding Human Fear Extinction: Insights from Psychophysiology.Current topics in behavioral neurosciences · 2023
    Article
  9. Review
  10. Deriving psychiatric symptom-based biomarkers from multivariate relationships between psychophysiological and biochemical measures.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Impaired inhibition as an intermediate phenotype for PTSD risk and treatment response.Progress in neuro-psychopharmacology & biological psychiatry · 2019
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

D T AchesonDepartment of Psychiatry, University of California San Diego, United States.
M A GeyerDepartment of Psychiatry, University of California San Diego, United States; Mental Illness Research, Education and Clinical Center, VA San Diego Healthcare System, United States.
D G BakerDepartment of Psychiatry, University of California San Diego, United States; Center for Excellence in Stress and Mental Health, VA San Diego Healthcare System, United States.
C M NievergeltDepartment of Psychiatry, University of California San Diego, United States; Center for Excellence in Stress and Mental Health, VA San Diego Healthcare System, United States.
K YurgilCenter for Excellence in Stress and Mental Health, VA San Diego Healthcare System, United States.
V B RisbroughDepartment of Psychiatry, University of California San Diego, United States; Center for Excellence in Stress and Mental Health, VA San Diego Healthcare System, United States. Electronic address: vrisbrough@ucsd.edu.
MRS-II Team
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

SENSORY GATING &HABITUATION IN SCHIZOPHRENIAR01MH042228 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRAFF, DAVID L. · 1987 to 2015
$6.5M
SENSORY GATING AND HABITUATION IN SCHIZOPHRENIAR37MH042228 · NIMH · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BRAFF, DAVID L. · 1993 to 2002
$1.3M
Role of COMTval158met in PTSD risk and treatment responseI01BX002558 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RISBROUGH, VICTORIA B · 2015 to 2018
–
BLRD VA I01 BX002558NIMH NIH HHS MH042228NIMH NIH HHS R01 MH042228NIMH NIH HHS R37 MH042228
6 · The paper itself

Abstract

backgroundPosttraumatic Stress Disorder (PTSD) is a major public health concern, especially given the recent wars in Iraq and Afghanistan. Nevertheless, despite a sharp increase in the incidence of psychiatric disorders in returning veterans, empirically based prevention strategies are still lacking. To develop effective prevention and treatment strategies, it is necessary to understand the underlying biological mechanisms contributing to PTSD and other trauma related symptoms.

methodsThe "Marine Resiliency Study II" (MRS-II; October 2011-October 2013) Neurocognition project is an investigation of neurocognitive performance in Marines about to be deployed to Afghanistan. As part of this investigation, 1195 Marines and Navy corpsmen underwent a fear conditioning and extinction paradigm and psychiatric symptom assessment prior to deployment. The current study assesses (1) the effectiveness of the fear potentiated startle paradigm in producing fear learning and extinction and (2) the association of performance in the paradigm with baseline psychiatric symptom classes (healthy: n=923, PTSD symptoms: n=42, anxiety symptoms: n=37, and depression symptoms: n=12).

resultsResults suggest that the task was effective in producing differential fear learning and fear extinction in this cohort. Further, distinct patterns emerged differentiating the PTSD and anxiety symptom classes from both healthy and depression classes. During fear acquisition, the PTSD symptom group was the only group to show deficient discrimination between the conditioned stimulus (CS+) and safety cue (CS-), exhibiting larger startle responses during the safety cue compared to the healthy group. During extinction learning, the PTSD symptom group showed significantly less reduction in their CS+ responding over time compared to the healthy group, as well as reduced extinction of self-reported anxiety to the CS+ by the end of the extinction session. Conversely, the anxiety symptom group showed normal safety signal discrimination and extinction of conditioned fear, but exhibited increased baseline startle reactivity and potentiated startle to CS+, as well as higher self-reported anxiety to both cues. The depression symptom group showed similar physiological and self-report measures as the healthy group. DISCUSSION: These data are consistent with the idea that safety signal discrimination is a relatively specific marker of PTSD symptoms compared to general anxiety and depression symptoms. Further research is needed to determine if deficits in fear inhibition vs. exaggerated fear responding are separate biological "domains" across anxiety disorders that may predict differential biological mechanisms and possibly treatment needs. Future longitudinal analyses will examine whether poor learning of safety signals provides a marker of vulnerability to develop PTSD or is specific to symptom state.

Indexed as

AdultAnxietyConditioning, ClassicalDepressionExtinction, PsychologicalFearHumansLearningLife Change EventsMaleMilitary PersonnelReflex, StartleResilience, PsychologicalStress Disorders, Post-TraumaticYoung AdultAnxietyExtinctionFearFear inhibitionMilitaryPTSDSafety signalStartle

Identifiers

PMID25444643
PMCPMC4345165
OpenAlexW1971067535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.